According to an October 30 Medscape post, Edoxaban (Savaysa, Daiichi-Sankyo) received a favorable vote, 9–1, in favor of release for once a day treatment at 30 and 60 mg to prevent non-valvular atrial fibrillation ischemic stroke. Edoxaban was found non-inferior to “in control” Coumadin in patients with mild to moderate renal impairment, but its performance in people with creatinine clearances over 80 mL/min was found to be inferior. The advisory committee vote is preliminary to FDA release of edoxaban, the final ruling could be weeks or months away.
Nov 1 2014
Comments (0)Anticoagulant Therapy
No comments here.